TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer.

MLA

Arimura, Akiko, et al. “TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer.” Cancers, vol. 16, no. 6, Mar. 2024, p. 1184. EBSCOhost, https://doi.org/10.3390/cancers16061184.

APA

Arimura, A., Sakai, K., Kaneshiro, K., Morisaki, T., Hayashi, S., Mizoguchi, K., Yamada, M., Kai, M., Ono, M., Nishio, K., Nakamura, M., & Kubo, M. (2024). TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. Cancers, 16(6), 1184. https://doi.org/10.3390/cancers16061184

Chicago

Arimura, Akiko, Kazuko Sakai, Kazuhisa Kaneshiro, Takafumi Morisaki, Saori Hayashi, Kimihisa Mizoguchi, Mai Yamada, et al. 2024. “TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer.” Cancers 16 (6): 1184. doi:10.3390/cancers16061184.